The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study
Sanjoy K Paul, Deepak L Bhatt, Olga Montvida
EUROPEAN HEART JOURNAL | OXFORD UNIV PRESS | Published : 2021
AIMS: The aim of this study was to evaluate the temporal pattern of amputations in patients with type 2 diabetes mellitus (T2DM), the risk of amputations by new and older anti-diabetic drugs (ADDs), and the interplay of peripheral artery disease (PAD) with therapy and amputation risk. METHODS AND RESULTS: Using Centricity Electronic Medical Records from USA, 3 293 983 patients with T2DM were identified: 169 739 received sodium-glucose cotransporter type-2 inhibitors (SGLT-2i; no exposure to incretins); 149 826 received glucagon-like peptide 1 receptor agonists [GLP-1RA, no SGLT-2i or dipeptidyl peptidase-4 inhibitor (DPP-4i) exposure]; 448 225 received DPP-4i (no exposure to GLP-1RA or SGLT-..View full abstract
S.K.P. and D.L.B. were responsible for the primary design of the study. O.M. conducted the data extraction. O.M. and S.K.P. jointly conducted the statistical analyses. The first draft of the manuscript was developed by S.K.P., and all authors contributed to the finalization of the manuscript. S.K.P. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Melbourne EpiCentre gratefully acknowledges the support from the National Health and Medical Research Council and the Australian Government's National Collaborative Research Infrastructure Strategy (NCRIS) initiative through Therapeutic Innovation Australia.